DrugPatentWatch Database Preview
Details for Patent: 7,759,308
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which drugs does patent 7,759,308 protect, and when does it expire?
Patent 7,759,308 protects SIGNIFOR LAR KIT and is included in one NDA.
This patent has forty-one patent family members in thirty-four countries.
Summary for Patent: 7,759,308
| Title: | Microparticles comprising somatostatin analogues |
| Abstract: | Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles. |
| Inventor(s): | Ahlheim; Markus (Staufen, DE), Ausborn; Michael (Lorrach, DE), Lambert; Olivier (Spechbach-le-Haut, FR), Riemenschnitter; Marc (Freiburg, DE) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 10/579,186 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Device; |
Drugs Protected by US Patent 7,759,308
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-004 | Jun 29, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-001 | Dec 15, 2014 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-005 | Jun 29, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-002 | Dec 15, 2014 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-003 | Dec 15, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,759,308
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0326602.0 | Nov 14, 2003 |
| United Kingdom | 0406241.0 | Mar 19, 2004 |
| PCT Information | |||
| PCT Filed | November 12, 2004 | PCT Application Number: | PCT/EP2004/012870 |
| PCT Publication Date: | May 26, 2005 | PCT Publication Number: | WO2005/046645 |
International Family Members for US Patent 7,759,308
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 047310 | Start Trial | |||
| Austria | 455537 | Start Trial | |||
| Australia | 2004289055 | Start Trial | |||
| Brazil | PI0416227 | Start Trial | |||
| Canada | 2541944 | Start Trial | |||
| China | 1878541 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
